Liver dysfunction associated with parenteral nutrition: What are the options?

Practical Gastroenterology

Volumn 30, Issue 12, 2006, Pages 49-68

  Lee, Vanessa ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT DISEASE; CHOLELITHIASIS; CHOLESTASIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; HISTOPATHOLOGY; HUMAN; INFANT DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; PARENTERAL NUTRITION; REVIEW; STEATOSIS; TREATMENT PLANNING;

EID: 33845931838     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Buchman AL. Complications of long-term home total patenteral nutrition: Their identification, prevention and treatment. Dig Dis Sci, 2001;46(1):1-18.
2. Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology, 1993;104(1):286-301.
3. Btaiche IF, Khalidi N. Parenteral nutrition-associated liver complications in children. Pharmacotherapy, 2002;22(2):188-211.
4. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med, 2000;132(7):525-532.
5. Fouin-Fortunet H, Le Quernec L, Erlinger S, Lerebours E, Colin R. Hepatic alterations during total parenteral nutrition in patients with inflammatory bowel disease: A possible consequence of lithocholate toxicity. Gastroenterology, 1982;82(5 Pt 1):932-937.
6. Tulikoura I, Huikuri K. Morphological fatty changes and function of the liver, serum free fatty acids, and triglycerides during parenteral nutrition. Scand J Gastroenterol, 1982; 17(2): 177-185.
7. Nanji AA, Anderson FH. Sensitivity and specificity of liver function tests in the detection of parenteral nutrition-associated cholestasis. JPEN, 1985;9(3):307-308.
8. Lindor KD, Fleming CR, Abrams A, Hirschkorn MA. Liver function values in adults receiving total parenteral nutrition. JAMA, 1979;241(22):2398- 2400.
9. Sheldon GF, Peterson SR, Sanders R. Hepatic dysfunction during hyperalimentation. Arch Surg, 1978;113(4):504-508.
10. Jacobson S, Ericsson JL, Obel AL. Histopathological and ultrastructural changes in the human liver during complete intravenous nutrition for seven months. Acta Chir Scand, 1971;137(4):335-349.
11. Bowyer BA, Fleming CR, Ludwig J, Petz J, McGill DB. Does long-term home parenteral nutrition in adult patients cause chronic liver disease? JPEN, 1985;9(1):11-17.
12. Messing B, Bories C, Kunstlinger F, Bernier JJ. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis? Gastroenterology, 1983;84(5 Pt 1):1012-1019.
13. Ito Y, Shils ME. Liver dysfunction associated with long-term total parenteral nutrition in patients with massive bowel resection. JPEN, 1991;15(3):271-276.
14. Stanko RT, Nathan G, Mendelow H, Adibi SA. Development of hepatic cholestasis and fibrosis in patients with massive loss of intestine supported by prolonged parenteral nutrition. Gastroenterology, 1987;92(1):197-202.
15. Nanji AA, Anderson FH. Cholestasis associated with parenteral nutrition develops more commonly with hematologic malignancy than with inflammatory bowel disease. JPEN, 1984;8(3):325.
16. Campos AC, Oler A, Meguid MM, Chen TY. Liver biochemical and histological changes with graded amounts of total parenteral nutrition. Arch Surg, 1990;125(4):447-450.
17. Meguid MM, Chen TY, Yang ZJ, Campos AC, Hitch DC, Gleason JR. Effects of continuous graded total parenteral nutrition on feeding indexes and metabolic concomitants in rats. Am J Physiol, 1991;260(1 Pt 1):E126-E140.
18. Keim NL. Nutritional effectors of hepatic steatosis induced by parenteral nutrition in the rat. JPEN, 1987;11(1):18-22.
19. Bengoa JM, Hanauer SB, Sitrin MD, Baker AL, Rosenberg IH. Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology, 1985;5(1):79-84.
20. Palmer RH, Ruban Z. Production of bile duct hyperplasia and gallstones by lithocholic acid. J Clin Invest, 1966;45(8):1255-1267.
21. Alverdy JC, Aoys E, Moss GS. Total parenteral nutrition promotes bacterial translocation from the gut. Surgery, 1988;104(2): 185-190.
22. Fleming CR. Hepatobiliary complications in adults receiving nutrition support. Dig Dis, 1994;12(4):191-198.
23. Steiger E, Hamilton C. Hepatobiliary-associated complications of home parenteral nutrition (HPN). Support Line, 2001;25(5):1-5.
24. Gramlich LM. Cyclic parenteral nutrition: Considerations of carbohydrate and lipid metabolism. Nutr Clin Pract, 1994;9(2):49-50.
25. Howard L, Ashley C. Management of complications in patients receiving home parenteral nutrition. Gastroenterology, 2003; 124(6):1651-1661.
26. Burstyne M, Jensen GL. Abnormal liver functions as a result of total parenteral nutrition in a patient with short-bowel syndrome. Nutrition, 2000;16(11-12):1090-1092.
27. Schloerb PR, Henning JF. Patterns and problems of adult total parenteral nutrition use in US academic medical centers. Arch Surg, 1998;133(1):7-12.
28. Zagara G, Locati L. Role of total parenteral nutrition in determining liver insufficiency in patients with cranial injuries, glucose vs glucose + lipids. Minerva Anestesiol, 1989;55(12):509-512.
29. Richardson TJ, Sgoutas D. Essential fatty acid deficiency in four adult patients during total parenteral nutrition. Am J Clin Nutr, 1975;28(3):258-263.
30. Collins FD, Sinclair AJ, Royle JP, Coats DA, Maynard AT, Leonard RF. Plasma lipids in human linoleic acid deficiency. Nutr Metab, 1971;13(3):150-167.
31. Allardyce DB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet, 1982;154(5):641-647.
32. Matuchansky C, Messing B, Jeejeebhoy KN, Beau P, Beliah M, Allard JP. Cyclical parenteral nutrition. Lancet, 1992;340(8819): 588-592.
33. Craig RM, Coy D, Green R, Meersman R, Rubin H, Janssen I. Hepatotoxicity related to total parenteral nutrition: Comparison of low-lipid and lipid-supplemented solutions. J Crit Care, 1994;9(2):111-113.
34. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev, 1994;52(10):327-339.
35. Shronts EP. Essential nature of choline with implications for total parenteral nutrition. J Am Diet Assoc, 1997;97(6):639-46, 649; quiz 647-648.
36. Buchman AL, Dubin M, Jenden D, Moukarzel A, Roch MH, Rice K, Gornbein J, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology, 1992;102(4 Pt 1):1363-1370.
37. Buchman AL. Choline deficiency during parenteral nutrition in humans. Nutr Clin Pract, 2003;18(5):353-358.
38. Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, Pownall H, et al. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: Proof of a human choline requirement: A placebo-controlled trial. JPEN, 2001;25(5)260-268.
39. Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, et al. Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology, 1995; 22(5):1399-1403.
40. Tao RC, Yoshimura NN. Carnitine metabolism and its application in parenteral nutrition. JPEN, 1980;4(5):469-486.
41. Worthley LI, Fishlock RC, Snoswell AM. Carnitine balance and effects of intravenous L-carnitine in two patients receiving long-term total parenteral nutrition. JPEN, 1984;8(6):717-719.
42. Bowyer BA, Miles JM, Raymond MW, Fleming CR. L-carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations. Gastroenterology, 1988;94(2):434-438.
43. Shatsky F, Borum PR. Should carnitine be added to parenteral nutrition solutions? Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition, 2000;15:152-154.
44. Worthley LI, Fishlock RC, Snoswell AM. Carnitine deficiency with hyperbilirubinemia, generalized skeletal muscle weakness and reactive hypoglycemia in a patient on long-term total parenteral nutrition: Treatment with intravenous L-carnitine. JPEN, 1983;7(2):176-180.
45. Wang WY, Liaw KY. Effect of a taurine-supplemented diet on conjugated bile acids in biliary surgical patients. JPEN, 1991;15(3):294-297.
46. Geggel HS, Ament ME, Heckenlively JR, Martin DA, Kopple JD. Nutritional requirement for taurine in patients receiving long-term parenteral nutrition. NEJM, 1985;312(3):142-146.
47. Grant JP, Snyder PJ. Use of L-glutamine in total parenteral nutrition. J Surg Res, 1988; 44(5):506-513.
48. Li SJ, Nussbaum MS, McFadden DW, et al. Addition of L-glutamine to total parenteral nutrition and its effects on portal insulin and glucagon and the development of hepatic steatosis in rats. J Surg Res 1990;48(5):421-426.
49. Burke DJ, Alverdy JC, Aoys E, Moss GS. Glutamine-supplemented total parenteral nutrition improves gut immune function. Arch Surg, 1989;124(12):1396-1399.
50. Kudsk KA, Wu Y, Fukatsu K, Zarzaur BL, Johnson CD, Wang R, Hanna MK. Glutamine-enriched total parenteral nutrition maintains intestinal interleukin-4 and mucosal immunoglobulin A levels. JPEN, 2000;24(5):270-274; discussion 274-275.
51. Hornsby-Lewis L, Shike M, Brown P, Klang M, Pearlstone D, Brennan MF. L-glutamine supplementation in home total parenteral nutrition patients: Stability, safety, and effects on intestinal absorption. JPEN, 1994;18(3):268-273.
52. Yu JC, Jiang ZM, Li DM. Glutamine: A precursor of glutathione and its effect on liver. W J Gastroenterol, 1999;5(2):143-146.
53. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, Brummer RJ, Arends JW, Deutz NE, Soeters PB. Glutamine and the preservation of gut integrity. Lancet, 1993;341(8857):1363-1365.
54. Dechelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coeffier M, Hecketsweiler B, Merle V, et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The french controlled, randomized, double-blind, multicenter study. Crit Care Med, 2006;34(3):598-604.
55. Matuchansky C, Morichau-Beauchant M, Druart F, Tapin J. Cyclic (nocturnal) total parenteral nutrition in hospitalized adult patients with severe digestive diseases, report of a prospective study. Gastroenterology, 1981;81(3):433-437.
56. Hwang TL, Lue MC, Chen LL. Early use of cyclic TPN prevents further deterioration of liver functions for the TPN patients with impaired liver function. Hepatogastroenterology, 2000;47(35): 1347-1350.
57. Bennett KM, Rosen GH. Cyclic total parenteral nutrition. Nutr Clin Pract, 1990;5(4):163-165.
58. Maini B, Blackburn GL, Bistrian BR, Flatt JP, Page JG, Bothe A, Benotti P, et al. Cyclic hyperalimentation: An optimal technique for preservation of visceral protein. J Surg Res, 1976;20(6):515-525.
59. Deitch EA. Infection in the compromised host. Surg Clin North Am, 1988;68(1):181-197.
60. Alverdy J, Chi HS, Sheldon GF. The effect of parenteral nutrition on gastrointestinal immunity, the importance of enteral stimulation. Ann Surg. 1985;202(6):681-684.
61. Freund HR, Muggia-Sullam M, LaFrance R, Enrione EB, Popp MB, Bjornson HS. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements. J Surg Res, 1985;38(4):356-363.
62. Lambert JR, Thomas SM. Metronidazole prevention of serum liver enzyme abnormalities during total parenteral nutrition. JPEN, 1985;9(4):501-503.
63. Capron JP, Gineston JL, Herve MA, Braillon A. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet, 1983;1(8322):446-447.
64. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications. Hepatology, 1998;28(6):1449-1453.
65. Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med, 2000;108(6):481-486.
66. Hori Y, Ohyanagi H. Protective effect of the intravenous administration of ursodeoxycholic acid against endotoxemia in rats with obstructive jaundice. Surg Today, 1997;27(2):140-144.
67. Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction; An experimental study. Hepatogastroenterology, 2002;49(44):497-500.
68. Beau P, Labat-Labourdette J, Ingrand P, Beauchant M. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J Hepatol 1994;20(2):240-244.
69. Lindor KD, Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report. Gastroenterology, 1991;101(1):250-253.
70. Kalfarentzos F, Spiliotis J, Chalmoukis A, Vagenas C, Vagenakis A. Gallbladder contraction after hormonal manipulations in normal subjects and patients under total parenteral nutrition. J Am Coll Nutr, 1992;11(1):17-20.
71. Sitzmann JV, Pitt HA, Steinborn PA, Pasha ZR, Sanders RC. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet, 1990;170(1):25-31.
72. Abad-Lacruz A, Gonzalez-Huix F, Esteve M, Fernandez-Banares F, Cabre E, Boix J, Acero D, et al. Liver function tests abnormalities in patients with inflammatory bowel disease receiving artificial nutrition: A prospective randomized study of total enteral nutrition vs total parenteral nutrition. JPEN, 1990;14(6):618-621.
73. Zamir O, Nussbaum MS, Bhadra S, Subbiah MT, Rafferty JF, Fischer JE. Effect of enteral feeding on hepatic steatosis induced by total parenteral nutrition. JPEN, 1994;18(1):20-25.
74. Kaminski DL, Adams A, Jellinek M. The effect of hyperalimentation on hepatic lipid content and lipogenic enzyme activity in rats and man. Surgery, 1980;88(1):93-100.